APLM Stock Overview
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
Apollomics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.47 |
| 52 Week High | US$6.45 |
| 52 Week Low | US$0.40 |
| Beta | 1.29 |
| 1 Month Change | -18.78% |
| 3 Month Change | -42.20% |
| 1 Year Change | -90.11% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -95.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| APLM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -7.6% | 0.4% | 1.0% |
| 1Y | -90.1% | 0.9% | 21.9% |
Return vs Industry: APLM underperformed the US Biotechs industry which returned 0.7% over the past year.
Return vs Market: APLM underperformed the US Market which returned 24.9% over the past year.
Price Volatility
| APLM volatility | |
|---|---|
| APLM Average Weekly Movement | 13.7% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: APLM's share price has been volatile over the past 3 months.
Volatility Over Time: APLM's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 45 | Guo-Liang Yu | www.apollomicsinc.com |
Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers.
Apollomics, Inc. Fundamentals Summary
| APLM fundamental statistics | |
|---|---|
| Market cap | US$42.15m |
| Earnings (TTM) | -US$172.60m |
| Revenue (TTM) | US$821.00k |
51.3x
P/S Ratio-0.2x
P/E RatioIs APLM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APLM income statement (TTM) | |
|---|---|
| Revenue | US$821.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$821.00k |
| Other Expenses | US$173.42m |
| Earnings | -US$172.60m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.93 |
| Gross Margin | 100.00% |
| Net Profit Margin | -21,023.26% |
| Debt/Equity Ratio | 10.3% |
How did APLM perform over the long term?
See historical performance and comparison